RNAi Therapeutics and Technology Market (3rd Edition): Focus on siRNA, miRNA, shRNA, sshRNA and DNA, 2022-2035
INTRODUCTION
RNAi therapeutics have garnered significant attention post the 2006 Nobel Prize that was awarded to Andrew Fire and Craig Mello for the discovery of RNA interference (RNAi). Subsequently, upon the approval of the first RNAi therapeutic, ONPATTRO®, in 2018, the field has witnessed a further surge in activity. Since then, three more RNAi based therapies, namely (in chronological order of approval year) GIVLAARI® (November 2019), LEQVIO® (October 2020) and OXLUMO™ (November 2020), have been approved by regulatory authorities. In addition, over 200 RNAi drug candidates are being evaluated across several clinical trials for the treatment of a wide range of disease indications. The ongoing research and development efforts are driven by the various advantages offered by these molecules; these include higher efficacy and enhanced potency at reduced effector molecule concentrations, over other modalities based on the anti-sense approach. RNAi-based therapies have also been identified as potential candidates for the treatment of COVID-19.
However, despite the numerous benefits offered by RNAi therapies, developers often face concerns related to the stability and targeted delivery of their candidates. In order to mitigate the aforementioned challenges, several players have developed novel technologies and delivery systems to ensure target specific delivery of these molecules. Such advancements have allowed therapy developers to shift their focus towards the use of RNAi therapeutics. Initiatives are also being undertaken to explore the vast potential associated with such therapeutic modalities for the control of disease-associated gene expression. In addition to effective gene silencing, these candidates can be deployed for applications related to precision medicine. Studies have also demonstrated the safety of RNAi therapeutics for in systemic delivery, paving the way for systemic applications of the therapy. The high specificity, efficiency, and long term and stable gene silencing capabilities of RNAi therapeutics are believed to offer the potential to revolutionize the biopharmaceutical industry. As a result, several big pharma players have also undertaken various initiatives in this field of research. In the last five years, USD 8.5 billion has been invested to enable the advancement of ongoing research efforts. Moreover, 3,000+ articles related to RNAi therapeutics and technologies have been published. It is also worth highlighting that over 2,100 patents have been filed / granted, highlighting the continuous pace of ongoing innovation in this field. Given the high research activity and ongoing technology advancements, the RNAi therapeutics market is poised to grow at a steady pace in the foreseen future.
SCOPE OF THE REPORT
The “RNAi Market: Therapeutics and Technologies (Focus on siRNA, miRNA, shRNA and DNA) (3rd Edition) by Key Therapeutic Areas (Oncological Disorders, Genetic Disorders, Metabolic Disorders, Hematological Disorders, Ophthalmic Disorders and Other Disorders), Route of Administration (Subcutaneous, Intravenous, Topical and Intradermal), Leading Industry Players, Type of RNAi Molecule (siRNA and shRNA) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and the likely future potential; associated with the RNAi therapeutics market, over the next decade. The study also includes a detailed analysis of key drivers and trends within this evolving market. Amongst other elements, the report features:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:
KEY QUESTIONS ANSWERED
Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state of the RNAi therapeutics market and its likely evolution in the short-mid term to long term.
Chapter 3 provides a general overview of RNAi therapeutics, including a discussion on the historical background. In addition, it includes information on the type of RNA molecule, along with information on their mechanisms of action and application areas. Further, it highlights the key advantages and challenges associated with this domain.
Chapter 4 includes information on over 200 RNAi pipeline candidates that are currently in different stages of development. It features a detailed analysis of the pipeline molecules, based on several relevant parameters, such as phase of development, target indication(s), key therapeutic areas, type of RNAi molecule, target genes, route of administration and special drug designation (if any).
Chapter 5 presents the detailed overview of players engaged in the development of RNAi therapeutics, along with information on their year of establishment, company size and location of headquarters. In addition, it features a logo landscape of product developers based on location of headquarters and company size.
Chapter 6 presents a three-dimensional bubble analysis of key players engaged in this domain, evaluating their developer strength (on the basis of employee count and years of experience) and product portfolio strength (on the basis of number of RNAi molecules across different phases of development, type of RNAi molecule offered, purpose of technology and target therapeutic areas).
Chapter 7 contains detailed profiles of drug candidates that are in the advanced stages of development (phase II/III and above). Each drug profile features information on the current development status of the drug, along with details on its developer, mechanism of action, route of administration, affiliated technology platform (if available), dosage and recent clinical trial results
Chapter 8 provides an analysis of the current market landscape of technology platforms available for the development of RNAi therapeutics, based on several relevant parameters such as, purpose of technology, type of molecule (s) delivered and type of cell (s) / tissue (s) targeted. In addition, the chapter includes an analysis on technology developer(s), highlighting their year of their establishment, company size and location of headquarters. The chapter also includes brief profiles of key RNAi-based drug discovery / development technology platforms and drug delivery technologies (shortlisted on the basis of competitiveness score). Each profile features details on the various pipeline molecules that have been / are being developed using the technology and insights from patents associated with the technology.
Chapter 9 presents the technology competitiveness analysis, benchmarking RNAi technologies, based on supplier power (in terms of in terms of company size and years of experience) and key technology specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.
Chapter 10 highlights the potential target indications (segregated by various therapeutic areas, including oncological disorders, infectious diseases, metabolic disorders, ophthalmic diseases and genetic disorders) that are currently the prime focus of companies engaged in the development of RNAi therapeutics.
Chapter 11 is an analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, current status, phase of development, type of RNAi molecule, enrolled patient population and regional distribution of trials.
Chapter 12 presents an analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) in this field.
Chapter 13 provides insights from a detailed patent analysis, presenting an overview of the filed / granted patents related to RNAi therapeutics since 2016, based on type of patent (granted patents, patent applications and others), publication year, regional applicability, CPC symbols, emerging focus areas and the leading industry / academic players (in terms of the number of patents filed / granted), and patent valuation. The chapter also includes a patent benchmarking analysis and a detailed valuation analysis.
Chapter 14 provides a detailed review of around 3,000 peer-reviewed, scientific articles related to research on RNAi therapeutics, based on several relevant parameters, such as year of publication, type of publication, popular keywords, top journals, top publishers, key copyright holders and key funding institutes.
Chapter 15 features an elaborate analysis the various partnerships related to RNAi therapeutics inked by players engaged in this domain, based on various parameters, such as the type of partnership, year of partnership, target disease indication, therapeutic area, type of RNAi molecule, financial details (wherever applicable), focus area of collaboration and most active players (in terms of number of partnerships).
Chapter 16 presents details on various investments various investments made by players engaged in this domain, during the period 2016-2021, based on several relevant parameters, such as year of funding, type of funding (seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other offerings), amount invested, type of RNAi molecule, most active players (in terms of number and amount of funding instances) and key investors (in terms of number of instances).
Chapter 17 highlights various commercialization strategies that can be adopted by drug developers engaged in this domain, across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing of the drug. The aspects covered in the chapter include details provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.
Chapter 18 discusses the use of miRNAs as potential biomarkers and enlists several miRNA biomarkers currently under investigation. In addition, the chapter provides the pipeline of diagnostic kits that have already been approved or are under development.
Chapter 19 provides information on the companies that are actively supporting the development of RNAi therapeutics market. These include contract manufacturers, contract researcher organizations and other service providers. In addition, the chapter includes an analysis based on parameters such as type of service provider, location of their headquarters and type of RNA molecule.
Chapter 20 provides an informed estimate of the annual clinical and commercial demand for RNAi therapeutics, taking into account the target patient population in ongoing and planned clinical trials of RNAi therapeutics, sponsored by both industry and non-industry players.
Chapter 21 presents an informed forecast analysis, highlighting the future potential of the market, till the year 2035. It also includes future sales projections of RNAi therapeutics that are either marketed or in advanced stages of clinical development (phase II/III and above). Sales potential and growth opportunity were estimated based on the target patient population, likely adoption rates, existing / future competition from other drug classes and the likely price of products. The chapter also presents a detailed market segmentation on the basis of [A] key therapeutic areas (oncological disorders, genetic disorders, metabolic disorders, hematological disorders, ophthalmic disorders and other disorders), [B] route of administration (subcutaneous, intravenous, topical and intradermal), [C] share of leading industry players, [D] type of RNAi molecule (siRNA and shRNA) and [E] key geographical regions (North America, Europe and Asia-Pacific).
Chapter 22 provides a detailed discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the RNAi therapeutics market.
Chapter 23 summarizes the entire report. It presents the list of key takeaways and offers our independent opinion on the current market scenario.
Chapter 24 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market.
Chapter 25 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 26 is an appendix, which provides the list of companies and organizations mentioned in the report.
- 1. PREFACE
- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Key Questions Answered
- 1.4. Chapter Outlines
- 2. EXECUTIVE SUMMARY
- 3. INTRODUCTION
- 3.1. Chapter Overview
- 3.2. Key Milestones and Historical Trends Related to RNAi
- 3.2.1. Discovery of RNAi
- 3.2.2. Development Efforts Focused on RNAi Therapies
- 3.3. Mechanism of RNAi
- 3.3.1. Components of RNAi
- 3.3.2. Cellular Mechanism
- 3.4. Types of RNAi Molecules
- 3.4.1. siRNA
- 3.4.2. miRNA
- 3.4.3. shRNA
- 3.5. Applications of RNAi
- 3.5.1 Functional Genomics
- 3.5.2 Therapeutics
- 3.5.3. Biotechnology
- 3.5.4. Genome-scale Screening
- 3.6. Advantages and Disadvantages of RNAi
- 3.6.1 Advantages of RNAi
- 3.6.2 Disadvantages of RNAi
- 3.6.3 Key Concerns Discussed During Regulatory Submissions (A Case Study)
- 3.7. Future Perspectives
- 4. MARKET OVERVIEW
- 4.1. Chapter Overview
- 4.2. RNAi Therapeutics: Marketed and Development Pipeline
- 4.2.1. Analysis by Type of RNAi Molecule
- 4.2.2. Analysis by Phase of Development
- 4.2.3. Analysis by Type of Molecule and Phase of Development
- 4.2.4. Analysis by Target Gene
- 4.2.5. Analysis by Therapeutic Area
- 4.2.6. Analysis by Route of Administration
- 4.2.7. Analysis by Special Drug Designation
- 4.2.8. Key Players
- 5. COMPETITIVE LANDSCAPE
- 5.1. Chapter Overview
- 5.2. RNAi Therapeutics: List of Developers
- 5.2.1. Analysis by Year of Establishment
- 5.2.2. Analysis by Company Size
- 5.2.3. Analysis by Location of Headquarters
- 5.2.4. Most Active Players: Analysis by Number of Drug Candidates
- 5.3 RNAi Therapeutics: Regional Landscape
- 6 COMPANY COMPETITIVENESS ANALYSIS
- 6.1. Chapter Overview
- 6.2. Assumptions and Key Parameters
- 6.3. Methodology
- 6.4. RNAi Therapeutics Developers: Company Competitive Analysis
- 6.4. RNAi Therapeutics Developers based in North America
- 6.5. RNAi Therapeutics Developers based in Europe
- 6.6. RNAi Therapeutics Developers based in Asia-Pacific and Rest of the World
- 7 APPROVED AND LATE STAGE RNAi THERAPEUTICS
- 7.1. Chapter Overview
- 7.2. Onpattro®
- 7.2.1. Drug Overview
- 7.2.2. Technology Overview
- 7.2.3. Current Development Status
- 7.2.4. Recent Clinical Trial Results
- 7.2.5. Recent Partnerships
- 7.3. Givlaari®
- 7.3.1. Drug Overview
- 7.3.2. Technology Overview
- 7.3.3. Current Development Status
- 7.3.4. Recent Clinical Trial Results
- 7.3.5. Recent Partnerships
- 7.4. Leqvio®
- 7.4.1. Drug Overview
- 7.4.2. Technology Overview
- 7.4.3. Current Development Status
- 7.4.4. Recent Clinical Trial Results
- 7.4.5. Recent Partnerships
- 7.5. Oxlumo™
- 7.5.1. Drug Overview
- 7.5.2. Technology Overview
- 7.5.3. Current Development Status
- 7.5.4. Recent Clinical Trial Results
- 7.5.5. Recent Partnerships
- 7.6. Fitusiran
- 7.6.1. Drug Overview
- 7.6.2. Technology Overview
- 7.6.3. Current Development Status
- 7.6.4. Recent Clinical Trial Results
- 7.7. Vutrisiran
- 7.7.1. Drug Overview
- 7.7.2. Technology Overview
- 7.7.3. Current Development Status
- 6.7.4. Recent Clinical Trial Results
- 7.8. SYL 1001
- 7.8.1. Drug Overview
- 7.8.2. Technology Overview
- 7.8.3. Current Development Status
- 7.8.4. Recent Clinical Trial Results
- 7.9. Vigil-EWS
- 7.9.1. Drug Overview
- 7.9.2. Technology Overview
- 7.9.3. Current Development Status
- 7.9.4. Recent Clinical Trial Results
- 7.10. SR-061
- 7.10.1. Drug Overview
- 7.10.2. Technology Overview
- 7.10.3. Current Development Status
- 7.11. Nedosiran
- 7.11.1. Drug Overview
- 7.11.2. Technology Overview
- 7.11.3. Current Development Status
- 7.11.4. Recent Clinical Trial Results
- 8 TECHNOLOGY PLATFORMS AND DELIVERY SYSTEMS
- 8.1. Chapter Overview
- 8.2. Components of RNAi Delivery Systems
- 8.2.1. RNAi Triggers
- 8.2.1.1. Asymmetric siRNA (cp-siRNA)
- 8.2.1.2. DNA Directed RNAi (ddRNAi)
- 8.2.1.3. Dicer Substrate siRNA (DsiRNA)
- 8.2.1.4. Naked siRNA
- 8.2.1.5. Self-Deliverable RNA (sd-RNA)
- 8.2.1.6. Self-Deliverable rxRNA (sd-rxRNA)
- 8.2.1.7. Unlocked Nucleobase Analog (UNA) Containing siRNA (UsiRNA)
- 8.2.2. Technology Platforms and Delivery Systems
- 8.2.2.1. Analysis by Purpose of Technology
- 8.2.2.2. Analysis by Type of Molecule (s) Delivered
- 8.2.2.3. Analysis by Type of Cell (s) / Tissue (s) Targeted
- 8.2.3. Technology Platforms: List of Developers
- 8.2.3.1. Analysis by Year of Establishment
- 8.2.3.2. Analysis by Company Size
- 8.2.3.3. Analysis by Location of Headquarters (Continent-wise)
- 8.2.3.4. Analysis by Location of Headquarters (Country-wise)
- 8.2.4. Technology Platform: Profiles
- 8.2.4.1. Conjugated Delivery Technologies
- 8.2.4.1.1. GalNAc Conjugate Delivery System, Alnylam Pharmaceuticals
- 8.2.4.1.1.1. Technology Overview
- 8.2.4.1.1.2 Pipeline Molecules in Development
- 8.2.4.1.1.3 Analyst’s Perspective
- 8.2.4.1.2. Protein Nanoparticle (PNP) Delivery Technology, Ariz Precision Medicine
- 8.2.4.1.2.1. Technology Overview
- 8.2.4.1.2.2. Pipeline Molecules in Development
- 8.2.4.1.2.3 Analyst’s Perspective
- 8.2.4.2.3 Targeted RNAi Molecule (TRiM) Platform, Arrowhead Pharmaceuticals
- 8.2.4.2.3.1. Technology Overview
- 8.2.4.2.3.2 Pipeline Molecules in Development
- 8.2.4.2.3.3 Analyst’s Perspective
- 8.2.4.2. Drug Discovery and Development Technologies
- 8.2.4.2.1. GalXC Conjugated RNAi Technology Platform, Dicerna Pharmaceuticals
- 8.2.4.2.1.1. Technology Overview
- 8.2.4.2.1.2 Pipeline Molecules in Development
- 8.2.4.2.1.3 Analyst’s Perspective
- 8.2.4.2.2. The Vigil Platform, Gradalis
- 8.2.4.2.2.1. Technology Overview
- 8.2.4.2.2.2 Pipeline Molecules in Development
- 8.2.4.2.2.3 Analyst’s Perspective
- 8.2.4.2.3. mRNAi GOLD Platform, Silence Therapeutics
- 8.2.4.2.3.1. Technology Overview
- 8.2.4.2.3.2 Pipeline Molecules in Development
- 8.2.4.2.3.3 Analyst’s Perspective
- 9 TECHNOLOGY COMPETITIVENESS ANALYSIS
- 9.1. Chapter Overview
- 9.2. Key Assumptions and Parameters
- 9.3. Methodology
- 9.4. Technology Competitiveness Analysis
- 9.4.1. Technology Competitiveness Analysis: Drug Delivery Technologies
- 9.4.2. Technology Competitiveness Analysis: Drug Discovery and Development Technologies
- 10 KEY THERAPEUTIC INDICATIONS
- 10.1. Chapter Overview
- 10.2. Oncological Disorders
- 10.2.1. Analysis by Target Indication and Phase of Development
- 10.2.2. Analysis by Type of RNAi Molecule
- 10.3. Infectious Diseases
- 10.3.1. Analysis by Target Indication and Phase of Development
- 10.3.2. Analysis by Type of RNAi Molecule
- 10.4. Metabolic Disorders
- 10.4.1. Analysis by Target Indication and Phase of Development
- 10.4.2. Analysis by Type of RNAi Molecule
- 10.5. Ophthalmic Diseases
- 10.5.1. Analysis by Target Indication and Phase of Development
- 10.5.2. Analysis by Type of RNAi Molecule
- 10.6. Genetic Disorders
- 10.6.1. Analysis by Target Indication and Phase of Development
- 10.6.2. Analysis by Type of RNAi Molecule
- 11 CLINICAL TRIAL ANALYSIS
- 11.1. Chapter Overview
- 11.2. Scope and Methodology
- 11.3. RNAi Therapeutics: Clinical Trial Analysis
- 11.3.1. Analysis by Trial Registration Year
- 11.3.2. Analysis by Trial Phase
- 11.3.3. Analysis by Trial Recruitment Status
- 11.3.4. Analysis by Type of Sponsor / Collaborator
- 11.3.5. Analysis by Type of RNAi Molecule
- 11.3.6. Analysis by Therapeutic Area
- 11.3.7. Geographical Analysis by Number of Clinical Trials
- 11.3.8. Geographical Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
- 11.3.9. Geographical Analysis by Number of Clinical Trials and Type of RNAi Molecule
- 11.3.10. Geographical Analysis by Number of Clinical Trials, Type of RNAi Molecule and Trial Phase
- 11.3.11. Geographical Analysis by Number of Clinical Trials and Therapeutic Area
- 11.3.12. Geographical Analysis by Number of Clinical Trials, Therapeutic Area and Trial Phase
- 11.3.13. Geographical Analysis of Enrolled Patient Population
- 11.3.14. Geographical Analysis of Enrolled Patient Population by Trial Phase and Trial Recruitment Status
- 11.3.15. Geographical Analysis of Enrolled Patient Population by Type of RNAi Molecule
- 11.3.16. Geographical Analysis of Enrolled Patient Population by Trial Phase and Type of RNAi Molecule
- 11.3.17. Geographical Analysis of Enrolled Patient Population by Therapeutic Area
- 11.3.18. Geographical Analysis of Enrolled Patient Population by Trial Phase and Therapeutic Area
- 11.4. Concluding Remarks
- 11.4.1. Key Therapeutic Candidates
- 11.4.2. Key Clinical Trials
- 12 KEY OPINION LEADERS
- 12.1. Chapter Overview
- 12.2. RNAi Therapeutics: Key Opinion Leaders
- 12.3. Analysis by Type of Organization
- 12.3.1. Analysis by Qualification of Key Opinion Leaders
- 12.3.2. Analysis by Geographical Location of KOLs
- 12.3.3. Analysis by Number of Affiliations
- 12.3.4. KOL Activeness v/s KOL Strength
- 12.4. Most Prominent KOLs: Analysis by KOL Strength
- 12.5. Benchmarking of Key Opinion Leaders (Roots Analysis versus Third Party Scoring)
- 13 PATENT ANALYSIS
- 13.1. Chapter Overview
- 13.2. Scope and Methodology
- 13.3. RNAi Therapeutics: Patent Analysis
- 13.3.1. Analysis by Type of Patent
- 13.3.2. Analysis by Publication Year
- 13.3.3. Analysis by Patent Status
- 13.3.4. Analysis by CPC Code
- 13.3.5. Analysis by Type of Organization
- 13.3.6. Analysis by Geography
- 13.3.5.1. North American Scenario
- 13.3.5.2. European Scenario
- 13.3.5.3 Asia-Pacific Scenario
- 13.3.6. Emerging Focus Areas
- 13.3.7. Leading Players: Analysis by Number of Patents
- 13.4. RNAi Therapeutics: Patent Benchmarking Analysis
- 13.4.1. Analysis by Key Patent Characteristics
- 13.5. RNAi Therapeutics: Patent Valuation Analysis
- 14 PUBLICATION ANALYSIS
- 14.1. Chapter Overview
- 14.2. Analysis Methodology and Key Parameters
- 14.3. RNAi Therapeutics: List of Publications
- 14.3.1. Analysis by Year of Publication
- 14.3.2. Analysis by Type of Publication
- 14.3.3. Most Popular Keywords
- 14.3.4. Top Journals: Analysis by Number of Publications
- 14.3.5. Top Publisher: Analysis by Number of Publications
- 14.3.6. Key Copyright Holders: Analysis by Number of Publications
- 14.3.7. Key Funding Institutes: Analysis by Number of Publications
- 15 RECENT PARTNERSHIPS
- 15.1. Chapter Overview
- 15.2. Partnership Models
- 15.3. RNAi Therapeutics: List of Partnerships
- 15.3.1. Analysis by Year of Partnership
- 15.3.2. Analysis by Type of Partnership
- 15.3.3. Analysis by Type of RNAi Molecule
- 15.3.4. Analysis by Scale of Partnership
- 15.3.5. Analysis by Therapeutic Area
- 15.3.6. Most Active Players: Analysis by Number of Partnerships
- 15.3.7. Analysis by Geography
- 15.3.7.1. Local and International Deals
- 15.3.7.2. Intercontinental and Intracontinental Deals
- 16 FUNDING AND INVESTMENT ANALYSIS
- 16.1. Chapter Overview
- 16.2. Types of Funding
- 16.3. RNAi Therapeutics: Funding and Investment Analysis
- 16.3.1. Analysis by Cumulative Funding Instances, 2016-2021
- 16.3.2. Analysis by Amount Invested
- 16.3.3. Analysis by Type of Funding
- 16.3.4. Analysis by Year and Type of Funding
- 16.3.5. Analysis of Amount Invested by Type of RNAi Molecule
- 16.3.6. Analysis of Amount Invested by Geography
- 16.3.7. Most Active Players
- 16.3.8. Key Investors
- 16.4. Concluding Remarks
- 17 KEY COMMERCIALIZATION STRATEGIES
- 17.1. Chapter Overview
- 17.2. Successful Drug Launch Strategy: ROOTS Framework
- 17.3. Successful Drug Launch Strategy: Product Differentiation
- 17.4. Commonly Adopted Commercialization Strategies based on Stage of Development of the Product
- 17.5. Approved RNAi Therapeutics
- 17.6. Key Commercialization Strategies Adopted by RNAi-based Therapy Developers
- 17.6.1. Strategies Adopted Before Therapy Approval
- 17.6.1.1. Participation in Global Events
- 17.6.1.2. Collaboration with Stakeholders and Pharmaceutical Firms
- 17.6.1.3. Indication Expansion
- 17.6.2. Strategies Adopted During / Post Therapy Approval
- 17.6.2.1. Participation in Global Events
- 17.6.2.2. Geographical Expansion
- 17.6.2.3. Patient Assistance Programs
- 17.6.2.4. Awareness Through Product Websites
- 17.6.2.5. Collaboration with Stakeholders and Pharmaceutical Firms
- 17.6.2.6. Aligning with Government Initiatives to Ensure High Adoption Rate
- 17.7. Concluding Remarks
- 18 RNAi IN DIAGNOSTICS
- 18.1. Chapter Overview
- 18.2. Key Characteristics of Biomarkers
- 18.3. Circulating miRNA Biomarkers
- 18.4. miRNA Biomarkers in Oncological Disorders
- 18.4.1. Importance of Early Cancer Detection
- 18.4.2. Cancer Screening and Diagnosis
- 18.4.3. Conventional Cancer Diagnostics
- 18.4.3.1. Biopsy
- 18.4.4. Need for Non-Invasive Approaches
- 18.4.5. Key Indications
- 18.4.5.1. Breast Cancer
- 18.4.5.2. Colorectal Cancer
- 18.4.5.3. Gastric Cancer
- 18.4.5.4. Hematological Cancer
- 18.4.5.4.1. Acute Myeloid Leukemia
- 18.4.5.4.2 Lymphoma
- 18.4.5.5. Lung Cancer
- 18.4.5.6. Prostate Cancer
- 18.5. miRNA Biomarkers in Cardiovascular Diseases
- 18.5.1. Key Indications
- 18.5.1.1. Coronary Artery Disease
- 18.5.1.2. Myocardial Infarction
- 18.6. miRNA Based Diagnostic Tests
- 19 SERVICE PROVIDERS FOR RNAi THERAPEUTICS
- 19.1. Chapter Overview
- 19.2. Analysis by Types of Service Providers
- 19.3. RNAi Therapeutics: List of CROs
- 19.3.1. Analysis by Year of Establishment
- 19.3.2. Analysis by Location of Headquarters
- 19.3.3. Analysis by Company Size
- 19.3.4. Analysis by Type of RNAi Molecule
- 19.4. RNAi Therapeutics: List of CMOs
- 19.4.1. Analysis by Year of Establishment
- 19.4.2. Analysis by Location of Headquarters
- 19.4.3. Analysis by Company Size
- 19.4.4. Analysis by Type of RNAi Molecule
- 19.5. RNAi Therapeutics: List of Consumables and Other Service Providers
- 19.5.1. Analysis by Year of Establishment
- 19.5.2. Analysis by Location of Headquarters
- 19.5.3. Analysis by Company Size
- 19.5.4. Analysis by Type of RNAi Molecule
- 20 DEMAND ANALYSIS
- 20.1. Chapter Overview
- 20.2. Assumptions and Methodology
- 20.3. Clinical Demand for RNAi Therapeutics
- 20.4. Commercial Demand for RNAi Therapeutics
- 21 MARKET SIZING AND OPPORTUNITY ANALYSIS
- 21.1. Chapter Overview
- 21.2. Scope and Limitations
- 21.3. Key Assumptions and Forecast Methodology
- 21.4. Global RNAi Therapeutics Market, 2022-2035
- 21.4.1. RNAi Therapeutics Market: Analysis by Type of RNAi Molecule
- 21.4.2. RNAi Therapeutics Market: Analysis by Therapeutic Area
- 21.4.3. RNAi Therapeutics Market: Analysis by Route of Administration
- 21.4.4. RNAi Therapeutics Market: Share of Leading Players
- 21.4.5. RNAi Therapeutics Market: Analysis by Geography
- 21.5. RNAi Therapeutics Market: Value Creation Analysis
- 21.6. RNAi Therapeutics Market: Product-wise Sales Forecasts
- 21.6.1. Onpattro®
- 21.6.1.1. Target Patient Population
- 21.6.1.2. Sales Forecast
- 21.6.1.3. Net Present Value
- 21.6.1.4. Value Creation Analysis
- 21.6.2. Givlaari™
- 21.6.2.1. Target Patient Population
- 21.6.2.2. Sales Forecast
- 21.6.2.3. Net Present Value
- 21.6.2.4. Value Creation Analysis
- 21.6.3. Leqvio®
- 21.6.3.1. Target Patient Population
- 21.6.3.2. Sales Forecast
- 21.6.3.3. Net Present Value
- 21.6.3.4. Value Creation Analysis
- 21.6.4. Oxlumo™
- 21.6.4.1. Target Patient Population
- 21.6.4.2. Sales Forecast
- 21.6.4.3. Net Present Value
- 21.6.4.4. Value Creation Analysis
- 21.6.5. Fitusiran
- 21.6.5.1. Target Patient Population
- 21.6.5.2. Sales Forecast
- 21.6.5.3. Net Present Value
- 21.6.5.4. Value Creation Analysis
- 21.6.6. Vutrisiran
- 21.6.6.1. Target Patient Population
- 21.6.6.2. Sales Forecast
- 21.6.6.3. Net Present Value
- 21.6.6.4. Value Creation Analysis
- 21.6.7. SYL-1001
- 21.6.7.1. Target Patient Population
- 21.6.7.2. Sales Forecast
- 21.6.7.3. Net Present Value
- 21.6.7.4. Value Creation Analysis
- 21.6.8. Vigil-EWS
- 21.6.8.1. Target Patient Population
- 21.6.8.2. Sales Forecast
- 21.6.8.3. Net Present Value
- 21.6.8.4. Value Creation Analysis
- 21.6.9. Nedosiran
- 21.6.9.1. Target Patient Population
- 21.6.9.2. Sales Forecast
- 21.6.9.3. Net Present Value
- 21.6.9.4. Value Creation Analysis
- 22 SWOT ANALYSIS
- 22.1. Chapter Overview
- 22.2. Strengths
- 22.3. Weaknesses
- 22.4. Opportunities
- 22.5. Threats
- 22.6 Comparison of SWOT Factors
- 22.6.1 Concluding Remarks
- 23 INTERVIEW TRANSCRIPT(S)
- 24 CONCLUSION
- 24.1. Chapter Overview
- 24.2. Key Takeaways
- 25 APPENDIX 1: TABULATED DATA
- 26 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook